Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting ( HAWTHORNE N.Y.--(BUSINESS WIRE)--Jun 4...)

Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Jun 4, 2007 - Acorda Therapeutics, Inc.(R) (Nasdaq: ACOR) today announced that the Company presented a "meta-analysis" or combined analysis of two clinical trials of Fampridine-SR in multiple sclerosis during a poster session at the Americas Committee for Treatment and Research in MS (ACTRIMS) Meeting in Washington, D.C. on Saturday, June 2, 2007. The poster, "Validation of Consistent Improvement in Walking Speed on the Timed 25 Foot Walk as a Measure of Clinically Meaningful Change," was presented by Andrew Goodman, M.D., Director of the Multiple Sclerosis Center at the University of Rochester.

The objective of the analysis was to validate a consistent response criterion as a measure of clinically meaningful change. A consistent timed walk responder was defined as a subject whose walking speeds for at least three of the four on-treatment visits were faster than the fastest speed across any of their five non-treatment visits. In both studies, Fampridine-SR treatment was associated with significantly increased probability of this response compared to placebo (p less than 0.001). Both clinical trials were double-blind, placebo-controlled, parallel group, multi-center studies. The analysis was designed after the data from the first study were available. A total of 501 patients were included in the analysis.

The clinical meaningfulness of this response criterion was assessed primarily by use of the 12-Item MS Walking Scale (MSWS-12), a questionnaire in which the patient rates the clinical impact of his or her walking disability on activities of daily life. Additional criteria for clinical meaningfulness included a seven-point Subject Global Impression (SGI) and a seven-point Clinician Global Impression (CGI). In the meta-analysis, timed-walk responders had significantly greater average improvements from baseline in the MSWS-12 score than the non-responders in both studies in
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Acorda Therapeutics Presents Data from its Phase 3 Study of Fampridine-SR in Multiple Sclerosis at the American Academy of Neurology Meeting
2. Acorda Therapeutics to Host Analyst and Investor Reception
3. Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data Selected for Scientific Highlights Program at the American Academy of Neurology Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23

Post Your Comments:

(Date:5/20/2013)... , May 20, 2013 Hyland ... healthcare industry by creating the Multi-Disciplinary Clinical Leadership ... variety of medical experts with diverse healthcare experience, ... healthcare industry to create new software solutions that ... specific needs of patients and staff. ...

(Date:5/20/2013)... 20, 2013 Enrollment of patients with Type ... dose-finding clinical trial of product candidate NewMet ™, ... for Type 2 diabetes. Elcelyx expects to complete enrollment ... June. Results of the trial,s primary endpoint of change ... and the read-out for long-term glucose lowering and weight ...

(Date:5/20/2013)... Rhythm announced today the presentation of results from ... gastroparesis symptoms among diabetic patients in the U.S. than ... patients with both type 1 and type 2 diabetes, ... the more common type 2 disease. ... Professor of Medicine at Harvard Medical School and Director ...

Breaking Medicine Technology:Hyland Software Forms Multi-Disciplinary Clinical Leadership Team to Augment Healthcare Solutions 2 Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2 Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3 Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4 Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2 Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3 Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4

[0] Hyland Software Forms Multi-Disciplinary Clinical Leadership Team to Augment Healthcare Solutions [0] Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes [0] Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S.

... 2008 Senesco,Technologies, Inc. ("Senesco" or the "Company") ... Mirmira, one of the Company,s funded researchers, will,be ... data,at two conferences in April 2008. Dr. Mirmira, ... of Virginia, is presently the,Eli Lilly Endowed Chair ...

... of Athletes ... - Team Type 1, - Spreads Messages of Hope to Others ... Ultimate Goal of Tour de France Competition, BRIDGEWATER, ... injection) will now become the primary sponsor of,Team Type 1, a team of amateur ...

Cached Medicine Technology:Senesco's Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences 2 Senesco's Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences 3 Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R) 2 Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R) 3 Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R) 4 Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R) 5

Senesco's Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R)

(Date:5/20/2013)... University of Southampton has shown that blind and visually ... to that used by bats and dolphins, to determine ... is published in the journal Hearing Research , ... could help blind people with spatial awareness and navigation. ... impairment and how to optimise echolocation ability in order ...

(Date:5/20/2013)... 6Webs.com is the leading supplier of ... 6Webs.com recently completed their assessments of the top alarm ... annually and the top home security system companies are ... technology, equipment and warranties to mention a few. ... team completed the home security reviews, numerous people claimed ...

(Date:5/20/2013)... Dermatologists are saying that new federally mandated labeling ... choices when it comes to products that provide ... required by the U.S. Food and Drug Administration ... will protect against skin cancer in addition to ... a sunscreen is water-resistant, according to the American ...

(Date:5/20/2013)... VHA Inc., the national health care ... population health improvement, announced a new offering to ... pursue population health management with a strategic ... the transition to value-based models of care. As ... of services, the offering integrates VHA expert advisory ...

(Date:5/20/2013)... Researchers at Lund University in Sweden have mapped ... atherosclerotic disease. No studies have previously examined whether ... study looked at coronary heart disease, ischemic stroke, ... in individuals whose siblings and parents have suffered ... showed that heredity is highest for atherosclerosis of ...

Breaking Medicine News(10 mins):Health News:New study finds blind people have the potential to use their 'inner bat' to locate objects 2 Health News:Best Home Alarm System Companies in 2013 Published by Leading Security Reviews Site - 6Webs.com 2 Health News:Revised Sunscreen Labels Should Help Consumers Make Wiser Choices 2 Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 2 Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 3 Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 4

[0] New study finds blind people have the potential to use their 'inner bat' to locate objects [0] Best Home Alarm System Companies in 2013 Published by Leading Security Reviews Site - 6Webs.com [0] Revised Sunscreen Labels Should Help Consumers Make Wiser Choices [0] VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings [0] Atherosclerotic disease heredity mapped in nationwide study

... MKL ) reported diluted net loss per share ... to diluted net income per share of $9.26,for the ... was $2.63 for the,nine months ended September 30, 2008 ... the same period of 2007. The results for both ...

... more targeted prevention efforts, researcher says , , TUESDAY, Nov. 4 ... Hispanics in the United States, a new study shows. , ... a type of beverage that is more associated with risky ... developed to target that beverage and that type of drinking," ...

... HAVEN, Conn., Nov. 4 VION,PHARMACEUTICALS, INC. (OTC Bulletin ... on Thursday, November 6, 2008 to,discuss its 2008 third ... 8:30 a.m. Eastern Time., To participate in the ... 213-8858 for international callers), at least 15 minutes,before the ...

... 4, 2008 Proactive measures can reduce hip fracture rates ... as 50 percent -- among those at risk, according to ... was published online on November 3 by The Journal ... , The largest study of its kind, the five-year study ...

... be Held at 8 a.m. EST -, SHENZHEN, ... (NYSE: NPD ) ("China Nepstar" or the "Company"), ... of directly operated,stores, announced today that the Company will ... before the market opens on,Wednesday, November 26, 2008., ...

... (Nasdaq: IRIX ) today reported financial results for ... the third quarter of 2008 was $12.0 million, an ... quarter of 2007. The,Company recorded net loss of $0.2 ... of 2008, an improvement over the net loss of ...

Markel Reports Third Quarter and Nine-Month Results Study Shows Hispanics Prefer Beer Vion Updates Conference Call Information Healthy bones program reduces hip fractures by 37 percent China Nepstar Chain Drugstore to Announce Third Quarter 2008 Financial Results on November 26 IRIDEX Reports Third Quarter 2008 Financial Results

... IMMULITE 1000 assays are designed ... and IMMULITE 1000, continuous random ... simplicity in both design and ... found in a wide variety ...

... Digoxin Assay is a homogeneous ... in the quantitative analysis of ... plasma. Kits are packaged specifically ... COBAS MIRA, COBAS MIRA S, ...

The Emit 2000 Digoxin Assay is a homogeneous enzyme immunoassay for use in the quantitative analysis of digoxin in human serum or plasma. Kits are conveniently packaged in Olympus Reagent Cartridges ...

Liquichek Rheumatoid Factor Control is a liquid trilevel control designed to monitor rheumatoid factor testing procedures, including nephelometric and latex agglutination methods....

Medicine Products:

IMMULITE Phenytoin Emit 2000 (Convenience Pack) Digoxin Assay OSR Digoxin Assay Liquichek Rheumatoid Factor Control